Abstract
BACKGROUND: Chronic pain (pain lasting three months or more) is an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Common types (excluding headache) include back pain, fibromyalgia, and neuropathic pain. Access to traditional face-to-face therapies can be restricted by healthcare resources, geography, and cost. Remote technology-based delivery of psychological therapies has the potential to overcome treatment barriers. However, their therapeutic effectiveness compared to traditional delivery methods requires further investigation. OBJECTIVES: To determine the benefits and harms of remotely-delivered psychological therapies compared to active control, waiting list, or treatment as usual for the management of chronic pain in adults. SEARCH METHODS: We searched for randomised controlled trials (RCTs) in CENTRAL, MEDLINE, Embase, and PsycINFO to 29 June 2022. We also searched clinical trials registers and reference lists. We conducted a citation search of included trials to identify any further eligible trials. SELECTION CRITERIA: We included RCTs in adults (≥ 18 years old) with chronic pain. Interventions included psychological therapies with recognisable psychotherapeutic content or based on psychological theory. Trials had to have delivered therapy remote from the therapist (e.g. Internet, smartphone application) and involve no more than 30% contact time with a clinician. Comparators included treatment as usual (including waiting-list controls) and active controls (e.g. education). DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodological procedures. MAIN RESULTS: We included 32 trials (4924 participants) in the analyses. Twenty-five studies delivered cognitive behavioural therapy (CBT) to participants, and seven delivered acceptance and commitment therapy (ACT). Participants had back pain, musculoskeletal pain, opioid-treated chronic pain, mixed chronic pain, hip or knee osteoarthritis, spinal cord injury, fibromyalgia, provoked vestibulodynia, or rheumatoid arthritis. We assessed 25 studies as having an unclear or high risk of bias for selective reporting. However, across studies overall, risk of bias was generally low. We downgraded evidence certainty for primary outcomes for inconsistency, imprecision, and study limitations. Certainty of evidence ranged from moderate to very low. Adverse events were inadequately reported or recorded across studies. We report results only for studies in CBT here. Cognitive behavioural therapy (CBT) versus treatment as usual (TAU) Pain intensity Immediately after treatment, CBT likely demonstrates a small beneficial effect compared to TAU (standardised mean difference (SMD) -0.28, 95% confidence interval (CI) -0.39 to -0.16; 20 studies, 3206 participants; moderate-certainty evidence). Participants receiving CBT are probably more likely to achieve a 30% improvement in pain intensity compared to TAU (23% versus 11%; risk ratio (RR) 2.15, 95% CI 1.62 to 2.85; 5 studies, 1347 participants; moderate-certainty evidence). They may also be more likely to achieve a 50% improvement in pain intensity (6% versus 2%; RR 2.31, 95% CI 1.14 to 4.66; 4 studies, 1229 participants), but the evidence is of low certainty. At follow-up, there is likely little to no difference in pain intensity between CBT and TAU (SMD -0.04, 95% CI -0.17 to 0.09; 8 studies, 959 participants; moderate-certainty evidence). The evidence comparing CBT to TAU on achieving a 30% improvement in pain is very uncertain (40% versus 24%; RR 1.70, 95% CI 0.82 to 3.53; 1 study, 69 participants). No evidence was available regarding a 50% improvement in pain. Functional disability Immediately after treatment, CBT may demonstrate a small beneficial improvement compared to TAU (SMD -0.38, 95% CI -0.53 to -0.22; 14 studies, 2672 participants; low-certainty evidence). At follow-up, there is likely little to no difference between treatments (SMD -0.05, 95% CI -0.23 to 0.14; 3 studies, 461 participants; moderate-certainty evidence). Quality of life Immediately after treatment, CBT may not have resulted in a beneficial effect on quality of life compared to TAU, but the evidence is very uncertain (SMD -0.16, 95% CI -0.43 to 0.11; 7 studies, 1423 participants). There is likely little to no difference between CBT and TAU on quality of life at follow-up (SMD -0.16, 95% CI -0.37 to 0.05; 3 studies, 352 participants; moderate-certainty evidence). Adverse events Immediately after treatment, evidence about the number of people experiencing adverse events is very uncertain (34% in TAU versus 6% in CBT; RR 6.00, 95% CI 2.2 to 16.40; 1 study, 140 participants). No evidence was available at follow-up. Cognitive behavioural therapy (CBT) versus active control Pain intensity Immediately after treatment, CBT likely demonstrates a small beneficial effect compared to active control (SMD -0.28, 95% CI -0.52 to -0.04; 3 studies, 261 participants; moderate-certainty evidence). The evidence at follow-up is very uncertain (mean difference (MD) 0.50, 95% CI -0.30 to 1.30; 1 study, 127 participants). No evidence was available for a 30% or 50% pain intensity improvement. Functional disability Immediately after treatment, there may be little to no difference between CBT and active control on functional disability (SMD -0.26, 95% CI -0.55 to 0.02; 2 studies, 189 participants; low-certainty evidence). The evidence at follow-up is very uncertain (MD 3.40, 95% CI -1.15 to 7.95; 1 study, 127 participants). Quality of life Immediately after treatment, there is likely little to no difference in CBT and active control (SMD -0.22, 95% CI -1.11 to 0.66; 3 studies, 261 participants; moderate-certainty evidence). The evidence at follow-up is very uncertain (MD 0.00, 95% CI -0.06 to 0.06; 1 study, 127 participants). Adverse events Immediately after treatment, the evidence comparing CBT to active control is very uncertain (2% versus 0%; RR 3.23, 95% CI 0.13 to 77.84; 1 study, 135 participants). No evidence was available at follow-up. AUTHORS' CONCLUSIONS: Currently, evidence about remotely-delivered psychological therapies is largely limited to Internet-based delivery of CBT. We found evidence that remotely-delivered CBT has small benefits for pain intensity (moderate certainty) and functional disability (moderate to low certainty) in adults experiencing chronic pain. Benefits were not maintained at follow-up. Our appraisal of quality of life and adverse events outcomes post-treatment were limited by study numbers, evidence certainty, or both. We found limited research (mostly low to very low certainty) exploring other psychological therapies (i.e. ACT). More high-quality studies are needed to assess the broad translatability of psychological therapies to remote delivery, the different delivery technologies, treatment longevity, comparison with active control, and adverse events.
Original language | English |
---|---|
Article number | CD013863 |
Journal | Cochrane Database of Systematic Reviews |
Volume | 2023 |
Issue number | 8 |
DOIs | |
Publication status | Published - 29 Aug 2023 |
Funding
Funding: VICI Innovative research grant, Netherlands Organisation for Scientific Research Other outcome measures: COMM, Pain Catastrophizing Scale, and number of visits to ED in the past 6 months and how many specifically for pain (past 6 months at baseline, past 30 days for subsequent assessment points) Funding: AR and LAM received funding from US National Institute on Drug Abuse (NIDA) (National Institutes of Health (R01DA026887)). HG received pilot grant from Centre for Technology and Behavioural Health (Dartmouth College to conduct qualitative process research component of this parent study). Conflicts of interest: none (CR: payment from a grant supporting the study (institution/past), financial relationship (employment/ongoing UNC-Chapel Hill), grants pending, receiving travel/accommodation/meeting expenses related to NIH grant review. LSP, TJS, DCM, MS, GW, DKA, RG, JLS, CM, JMJ, DSC: payment from a grant supporting the study (institution/past). MS: employment at EMG Serono Inc, ownership of stock in BMS, AbbVie, Abbott labs. GW: consultancy payment/honorarium (ongoing), fees for participating in review activities, payment for writing/reviewing manuscript. DKA: consultation fee for honorarium from UNC-Chapel Hill. RG: employment with Memorial Hospital of RI. JLS: employment at UNC-Chapel Hill. CM: employment at Duke. CP: employment at UNC-Chapel Hill. JMJ: consultancy and grants pending. FJK: nothing to declare). ment of congress attendance and travel costs, and payments for lectures with Psychotherapy Training Institutes. HB, DL, and MB received consultancy fees, reimbursement of congress attendance, and travel costs, and payments for lectures with the Psychotherapy and Psychiatry Associations and Psychotherapy Training Institutes (discussing E-Mental-Health topics). They have been beneficiaries of study support (third-party funding) from several public funding organisations. DE has shares in GET.ON Institut GmbH, which works to transfer research findings on internet-and mobile phone-based health interventions into routine care. DE has received payments from several companies and health insurance providers for advice on use of internet-based interventions. He has received payments for lectures delivered for Psychotherapy and Psychiatry Associations and has been beneficiary of third-party funding from health insurance providers. DL is minor stakeholder of the GET.ON Institut GmbH, which aims to transfer scientific knowledge related to this research into routine health care. MB, HB, DE, and DL were not involved in the data analysis". Cochrane Review Group funding acknowledgement: this project is funded by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Pain, Palliative and Supportive Care Review Group (PaPaS). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Cochrane PaPaS supported the authors in the development of this review. We thank Joanne Abbott for designing the search strategy. We thank Iris Gordon, Information Specialist for Cochrane Eyes and Vision Review Group, for peer reviewing the search strategy. The following people conducted the editorial process for this article: Sign-off Editor (final editorial decision): Neil O’Connell, Brunel University London; Managing Editor (selected peer reviewers, collated peer-reviewer comments, provided editorial guidance to authors, edited the article): Sam Hinsley, Central Editorial Service; Editorial Assistant (conducted editorial policy checks and supported editorial team): Sara Hales-Brittain, Central Editorial Service; Copy Editor (copy editing and production): Faith Armitage, Copy Editor, Cochrane Central Production Service; Mary Anna Rice, Senior Copy Editor, J&J Editorial Peer-reviewers (provided comments and recommended an editorial decision): Dokyoung Sophia You, Stanford University (clinical/content review); Brian Duncan, Consumer Reviewer, Cochrane (consumer review), Nuala Livingstone, Cochrane Evidence Production and Methods Directorate (methods review), Ina Monsef, Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany (search review). One additional peer reviewer provided clinical peer review but chose not to be publicly acknowledged. Sign-off Editor (final editorial decision): Neil O’Connell, Brunel University London; Managing Editor (selected peer reviewers, collated peer-reviewer comments, provided editorial guidance to authors, edited the article): Sam Hinsley, Central Editorial Service; Editorial Assistant (conducted editorial policy checks and supported editorial team): Sara Hales-Brittain, Central Editorial Service; Copy Editor (copy editing and production): Faith Armitage, Copy Editor, Cochrane Central Production Service; Mary Anna Rice, Senior Copy Editor, J&J Editorial Peer-reviewers (provided comments and recommended an editorial decision): Dokyoung Sophia You, Stanford University (clinical/content review); Brian Duncan, Consumer Reviewer, Cochrane (consumer review), Nuala Livingstone, Cochrane Evidence Production and Methods Directorate (methods review), Ina Monsef, Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany (search review). One additional peer reviewer provided clinical peer review but chose not to be publicly acknowledged. We would like to thank Bethan Copsey and Andrew Moore for providing statistical advice. We thank Josefin Dufva for helping transfer the extracted data into the review tables. Funding: doctoral dissertation of HDS and was supported by financial grant from Health Sciences Centre Foundation, Winnipeg, Manitoba, Canada Funding: Uppsala-Örebro Regional Research Council, grants RFR-845561 and RFR-930098, and Centre for Clinical Research, Västerås Funding: St Vincent’s Clinic Foundation (Sydney, Australia), Motor Accidents Authority, NSW Government (now State Insurance Regulatory Authority (SIRA)), and Australian National Health and Medical Research Council (NHMRC) and Medical Research Future Foundation (MRFF) Other outcome measures: Revised Fibromyalgia Impact Questionnaire, Hospital Anxiety and Depression Scale, Pain Self-Efficacy Questionnaire, Pain Responses Self-Statements (Catastrophising and Coping subscales), Fatigue Symptom Inventory, TAMPA Scale of Kinesophobia, Medical Outcomes Study Short Form (SF-12) Funding: LNF received funding from Canadian Institutes of Health and Faculty of Graduate Students and Research (University of Regina). HH was funded by Canadian Institutes of Health Research, Saskatchewan Health Research Foundations, and Rx & D Health Research Foundation. Pain Course development was funded by Macquarie University, Australian National Health and Medical Research Council, and Australian New South Wales Motor Accidents Authority. Other outcome measures: Brief Pain Inventory – interference scale, treatment completion measured as those completing at least 7 of 10 sessions (defined a priori), additional intervention experience items and open-ended questions (pg. 1478), Patient Global Impression of Change Scale, Pain-related distress, health care and medication use, CPAQ-8, Experiences Questionnaire (decentering), CAQ-8 Funding: International Association for the Study of Pain John J. Bonica Trainee Fellowship grant awarded to WS. Guy's and St. Thomas's Charity provided funding for the development of the online treatment materials. Funding: grant numbers R01-AR050044 (NIAMS/NIH) and DAMD 17-00-2-0018 (Department of Defense) Other outcome measures: Catastrophising subscale of the Coping Strategies Questionnaire; thoughts, attitudes, and opinions about pain (Pain and Impairment Relationship Scale); and acceptance of chronic pain (Chronic Pain Acceptance Questionnaire) Funding: MB was sponsored in part by the Multidisciplinary Pain centres at Uppsala University Hospital. GA was sponsored in part by Linköping University, Swedish Council for Working and Life Research, and agrant from Rehsam/Vårdalsstiftelsen. Funding: GA was sponsored in part by a grant from Linköping University, a grant from Rehsam/ Vårdalsstiftelsen, and the Swedish Council for Working and Life Research Conflicts of interest: DCT consulted for Pfizer, Nektar, Develco, Ironwood, GlaxoSmithKline, Mallincrodt, Orexo, Xydnia. RKP's organisation received funding from AstraZeneca and Pfizer (past 3 years). LAM has affiliation with HealthSim, LLC (company that developed the web-based platform for this study). Managed through LAM and her academic institution. No other conflicts reported. Funding: none declared in paper, but trial registry reports funding from Wissenschaftliche GesellschaN Freiburg Funding: National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number R43 AR052569) Conflicts of interest: none. However, the following people were acknowledged as contributors to the development of the intervention and assistance with the research: Dr Judith Turner, Dr Charles Chabal, Ms Tasha Mikko, and Ms KrisAnn Schmitz. Other outcome measures: miscellaneous: Pain Self-efficacy Questionnaire, Tampa Scale of Kinesopho-bia, Pain Responses Self-Statements Scale Funding: research was enabled by funding from the Motor Accident's Authority of New South Wales. BFD is supported by a National Health and Medical Research Council (NHMRC) Public Health Fellowship. Conflicts of interest: JLMB, GA, and HB are authors and developers of ACTonPain. DDE possesses shares in GET.ON Instituts Gesundheits Trainings and has received payments from several companies and health insurance providers (Lantern Inc., Minddistrict Holding, BARMER, Techniker Krankenkasse, Schön Kliniken, Agaplesion Kliniken, Ebel Kliniken) for advice on use of Internet-based interventions. He has received payments for lectures from Federal Psychotherapy Association (Bundespsychother-apeutenkammer) and psychotherapy state associations Hesse and Lower Saxony and has been beneficiary of third-party funding from health insurance provider BARMER, German Statutory Pension Insurance Scheme (DRV), Social Insurance for Agriculture, Forestry, and Horticulture (SVLFG), and Accident Insurance State Fund of North Rhine–Westphalia (Unfallkasse NRW). LS received payments for lectures on online-based psychotherapy from Freiburg Institute for Training in Cognitive Therapy (Freiburger Ausbildungsinstitut für Verhaltenstherapie (FAVT GmbH)) and Institute for Training in Psychotherapy, Saarland University (Weiterbildungsinstitut für Psychotherapie and der Universität des Saarlandes (WIPS GmbH)). HB received consultancy fees from Federal Psychotherapy Association (Bun-despsychotherapeutenkammer) and reimbursement of congress attendance, travel costs, and payments for lectures from the Federal Psychotherapy Association, psychotherapy state association of Baden-Württemberg, and Community Psychiatry Confederation (Dachverband für Gemeindepsychia-trie). He has been the beneficiary of study support (third-party funding) from health insurance provider BARMER GEK; Social Insurance for Agriculture, Forestry, and Horticulture (SVLFG); and the German Statutory Pension Insurance Scheme (DRV). He has received payments for lectures on online-based psychotherapy from Freiburg Institute for Training in Cognitive Therapy (Freiburger Ausbildungsinstitut für Verhaltenstherapie (FAVT GmbH)). SP has no conflicts. Conflicts of interest: KLB received grants from National Health and Medical Research Council during the conduct of the study; personal fees from Physitrack, ASICS Oceania, Peking University, and Brigham and Women’s Hospital outside submitted work; and other support from ASICS Oceania outside the submitted work. RKN received grants from National Health and Medical Research Council during conduct of study. FD received grants from National Health and Medical Research Council during conduct of study and personal fees from Elsevier Oracle outside submitted work. PWH received grants from the National Health and Medical Research Council during the conduct of the study. RSH received grants from National Health and Medical Research Council and Australian Research Council Future Fellowship during conduct of study; grant from Medibank Better Health Foundation; and other support from ASICS Oceania outside submitted work. Remaining authors have no conflicts of interest.
Funders | Funder number |
---|---|
Accident Insurance State Fund of North Rhine–Westphalia | |
Australian New South Wales Motor Accidents Authority | |
Canadian Institutes of Health and Faculty of Graduate Students and Research | |
Joanne Abbott | |
Johnston County Osteoarthritis Project | S1734, S043, S3486 |
Medical Research Future Foundation | |
Motor Accident's Authority of New South Wales | |
Motor Accidents Authority | |
NIAMS Multidisciplinary Clinical Research Center | 5-P60-AR49465, P60-AR064166 |
NIAMS Multipurpose Arthritis and Musculoskeletal Disease Center | 5-P60-AR30701 |
Prevention/Association of Schools of Public Health | |
SVLFG | |
Social Insurance for Agriculture, Forestry, and Horticulture | |
Swedish Council for Working and Life Research | |
Versus Arthritis National Institute for Health Research | |
Washington State Life Sciences Discovery Fund | LSDF 08–02 |
National Institutes of Health | DAMD 17-00-2-0018, R01DA026887 |
U.S. Department of Defense | |
National Institute on Drug | |
Centers for Disease Control and Prevention | |
National Institute of Arthritis and Musculoskeletal and Skin Diseases | R43 AR052569 |
AstraZeneca | |
Stanford University | |
Health Sciences Centre Foundation | |
University of Regina | |
Health Research Foundation | |
St. Vincent's Clinic Foundation | |
Regionala Forskningsrådet Uppsala/Örebro | RFR-930098, RFR-845561 |
Canadian Institute of Health Research | |
Saskatchewan Health Research Foundation | |
National Institute for Health and Care Research | |
Australian Research Council | |
National Health and Medical Research Council | |
Macquarie University | |
Nederlandse Organisatie voor Wetenschappelijk Onderzoek | |
Linköpings Universitet | |
Akademiska Sjukhuset | |
Brunel University | |
Peking University | |
Universität zu Köln | |
State Insurance Regulatory Authority | |
Universitätsklinikum Köln | |
Medibank Better Health Foundation |